GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins

Chemistry and Biology

Volumn 10, Issue 12, 2003, Pages 1255-1266

  Meijer, Laurent ^a,b   Skaltsounis, Alexios Leandros ^c   Magiatis, Prokopios ^c   Polychronopoulos, Panagiotis ^c   Knockaert, Marie ^a   Leost, Maryse ^a   Ryan, Xiaozhou P ^b   Vonica, Claudia Alin ^b   Brivanlou, Ali ^b   Dajani, Rana ^e   Crovace, Claudia ^d   Tarricone, Cataldo ^d   Musacchio, Andrea ^d   Roe, S Mark ^e   Pearl, Laurence ^e   Greengard, Paul ^b  

^a STATION BIOLOGIQUE   (France)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; GASTROPODA; INDIGOFERA; MOLLUSCA; TYRIA;

EID: 0346875916     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2003.11.010     Document Type: Article

References (69)

1. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2:2001;769-776.
2. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3 in cellular signaling. Prog. Neurobiol. 65:2001;391-426.
3. Eldar-Finkelman H. Glycogen synthase kinase 3. an emerging therapeutic target Trends Mol. Med. 8:2002;126-132.
4. Kaytor M.D., Orr H.T. The GSK3β signaling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 12:2002;275-278.
5. Doble B.W., Woodgett J.R. GSK-3. tricks of the trade for a multi-tasking kinase J. Cell Sci. 116:2003;1175-1186.
6. Ding Y., Dale T. Wnt signal transduction. kinase cogs in a nano-machine Trends Biochem. Sci. 27:2002;327-329.
7. Li X., Bijur G.N., Jope R.S. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4:2002;137-144.
8. Bijur G.N., Jope R.S. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J. Biol. Chem. 276:2001;37436-37442.
9. Crowder R.J., Freeman R.S. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J. Biol. Chem. 275:2000;34266-34271.
10. Culbert A.A., Brown M.J., Frame S., Hagen T., Cross D.A., Bax B., Reith A.D. GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett. 507:2001;288-294.
11. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W., Lee C.M. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. USA. 97:2000;11074-11079.
12. Cross D.A., Culbert A.A., Chalmers K.A., Facci L., Skaper S.D., Reith A.D. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77:2001;94-102.
13. Bijur G.N., De Sarno P., Jope R.S. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J. Biol. Chem. 275:2000;7583-7590.
14. Song L., De Sarno P., Jope R.S. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J. Biol. Chem. 277:2002;44701-44708.
15. Carmichael J., Sugars K.L., Bao Y.P., Rubinsztein D.C. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277:2002;33791-33798.
16. You Z., Saims D., Chen S., Zhang Z., Guttridge D.C., Guan K.L., MacDougald O.A., Brown A.M., Evan G., Kitajewski J.et al. Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J. Cell Biol. 157:2002;429-440.
17. Hashimoto M., Sagara Y., Langford D., Everall I.P., Mallory M., Everson A., Digicaylioglu M., Masliah E. Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J. Biol. Chem. 277:2002;32985-32991.
18. Li M., Wang X., Meintzer M.K., Laessig T., Birnbaum M.J., Heidenreich K.A. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol. Cell. Biol. 20:2000;9356-9363.
19. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:2001;27-39.
20. Jackson G.R., Wiedau-Pazos M., Sang T.-K., Wagle N., Brown C.A., Massachi S., Geschwind D.H. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 34:2002;509-519.
21. Martinez A., Castro A., Dorronsoro I., Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22:2002;373-384.
22. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:2000;95-105.
23. Patel S., Yenush L., Rodriguez P.L., Serrano R., Blundell T.L. Crystal structure of an enzyme displaying both inositol-polyphosphate-1-phosphatase and 3′-phosphoadenosine-5′-phosphate phosphatase activities. a novel target of lithium therapy J. Mol. Biol. 315:2002;677-685.
24. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.-M.et al. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease-A property common to most CDK inhibitors? J. Biol. Chem. 276:2001;251-260.
25. Knockaert M., Viking K., Schmitt S., Leost M., Mottram J., Kunick C., Meijer L. Intracellular targets of paullones. identification by affinity chromatography using immobilized inhibitor J. Biol. Chem. 277:2002;25493-25501.
26. Hoessel R., Leclerc S., Endicott J., Noble M., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D.et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1:1999;60-67.
27. Davies T.G., Tunnah P., Meijer L., Marko D., Eisenbrand G., Endicott J.A., Noble M.E.M. Inhibitor binding to active and inactive CDK2. The crystal structure of a CDK2-cyclin A/indirubin-5-sulphonate. Structure. 9:2001;389-397.
28. Balfour-Paul, J. (1998). Indigo. (London:British Museum Press).
29. Maugard T., Enaud E., Choisy P., Legoy M.D. Identification of an indigo precursor from leaves of Isatis tinctoria (Woad). Phytochemistry. 58:2001;897-904.
30. MacNeil I.A., Tiong C.L., Minor C., August P.R., Grossman T.H., Loiacono K.A., Lynch B.A., Phillips T., Narula S., Sundaramoorthi R.et al. Expression and isolation of antimicrobial small molecules from soil DNA libraries. J. Mol. Microbiol. Biotechnol. 3:2001;301-308.
31. Gillam E.M.J., Notley L.M., Cai H., DeVoss J.J., Guengerich F.P. Oxidation of indole by cytochrome P450 enzymes. Biochemistry. 39:2000;13817-13824.
32. Cooksey C.J. Tyrian purple. 6,6'-dibromoindigo and related compounds Mol. 6:2001;736-769.
33. Adachi J., Mori Y., Matsui S., Takigami H., Fujino J., Kitagawa H., Miller C.A. 3rd, Kato T., Saeki K., Matsuda T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 276:2001;31475-31478.
34. Tang W., Eisenbrand G. Chinese Drugs of Plant Origin. Chemistry, Pharmacology, and Use in Traditional and Modern Medicine:1992;Springer-Verlag, Heidelberg, Germany.
35. Xiao Z., Hao Y., Liu B., Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma. 43:2002;1763-1768.
36. Friedländer P. Uber den Farbstoff des antiken Purpurs aus Murex brandaris. Angew. Chem. 22:1909;2492-2494.
37. Fouquet H., Bielig H.J. Biological precursors and genesis of tyrian-purple. Angew. Chem. Int. Ed. Engl. 10:1971;816-817.
38. Dajani R., Fraser E., Roe S.M., Young N., Good V., Dale T.C., Pearl L.H. Crystal structure of glycogen synthase kinase 3β structural basis for phosphate-primed substrate specificity and autoinhibition Cell. 105:2001;721-732.
39. ter Haar E., Coll J.T., Austen D.A., Hsiao H.M., Swenson L., Jain J. Structure of GSK3β reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8:2001;593-596.
40. nck5a complex. Mol. Cell. 8:2001;657-669.
41. van Noort M., Meeldijk J., van der Zee R., Destree O., Clevers H. Wnt signaling controls the phosphorylation status of beta-catenin. J. Biol. Chem. 277:2002;17901-17905.
42. Huelsken J., Birchmeier W. New aspects of Wnt signaling pathways in higher vertebrates. Curr. Opin. Genet. Dev. 11:2001;547-553.
43. Elbi C., Misteli T., Hager G.L. Recruitment of dioxin receptor to active transcription sites. Mol. Biol. Cell. 13:2002;2001-2015.
44. Hughes K., Nikolakaki E., Plyte S.E., Totty N.F., Woodgett J.R. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 12:1993;803-808.
45. Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V., Dale T.C., Pearl L.H. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 22:2003;494-501.
46. Shaw M., Cohen P., Alessi D.R. Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett. 416:1997;307-311.
47. Glinka A., Wu W., Onichtchouk D., Blumenstock C., Niehrs C. Head induction by simultaneous repression of Bmp and Wnt signalling in Xenopus. Nature. 389:1997;517-519.
48. Carnac G., Kodjabachian L., Gurdon J.B., Lemaire P. The homeobox gene Siamois is a target of the Wnt dorsalisation pathway and triggers organiser activity in the absence of mesoderm. Development. 122:1996;3055-3065.
49. Kessler D.S. Siamois is required for formation of Spemann's organizer. Proc. Natl. Acad. Sci. USA. 94:1997;13017-13022.
50. Zeng L., Fagotto F., Zhang T., Hsu W., Vasicek T.J., Perry W.L. 3rd, Lee J.J., Tilghman S.M., Gumbiner B.M., Costantini F. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 90:1997;181-192.
51. Baker J.C., Beddington R.S., Harland R.M. Wnt signaling in Xenopus embryos inhibits bmp4 expression and activates neural development. Genes Dev. 13:1999;3149-3159.
52. Bain J., McLauchlan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors. an update Biochem. J. 371:2003;199-204.
53. Williams D.H., Mitchell T. Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. Curr. Opin. Pharmacol. 2:2002;567-573.
54. Leost M., Schultz C., Link A., Wu Y.-Z., Biernat J., Mandelkow E.-M., Bibb J.A., Snyder G.L., Greengard P., Zaharevitz D.W.et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267:2000;5983-5994.
55. Dorronsoro I., Castrob A., Martinez A. Inhibitors of glycogen synthase kinase-3. future therapy for unmet medical needs? Expert Opin. Ther. Patents. 12:2002;1-10.
56. Bhat R.V., Budd S.L. GSK3beta signalling. casting a wide net in Alzheimer's disease Neurosignals. 11:2002;251-261.
57. Gozes I. Tau as a drug target in Alzheimer's disease. J. Mol. Neurosci. 19:2002;337-338.
58. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., Sato K. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl. Acad. Sci. USA. 100:2003;6370-6375.
59. De Ferrari G.V., Chacon M.A., Barria M.I., Garrido J.L., Godoy J.A., Olivares G., Reyes A.E., Alvarez A., Bronfman M., Inestrosa N.C. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiatry. 8:2003;195-208.
60. Inestrosa N., De Ferrari G.V., Garrido J.L., Alvarez A., Olivares G.H., Barria M.I., Bronfman M., Chacon M.A. Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem. Int. 41:2002;341-344.
61. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 423:2003;435-439.
62. Larner A.J. Alzheimer's disease. targets for drug development Mini Rev. Med. Chem. 2:2002;1-9.
63. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., Gaynor K., LaFrancois J., Wang L., Kondo T.et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 38:2003;555-565.
64. Nieuwkoop P.D., Faber J. Normal Table of Xenopus laevis. 1967;North Holland Publishing Co, Amsterdam.
65. Wallace A.C., Laskowski R.A., Thornton J.M. Ligplot. a program to generate schematic diagrams of protein-ligand interactions Protein Eng. 8:1995;127-134.
66. DeLano, W.L. (2002). The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA.
67. Carson M. Ribbons 2.0. J. Appl. Crystallogr. 24:1991;958-961.
68. Bhat R., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., Radesater A.C., Jerning E., Markgren P.O., Borgegard T.et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278:2003;45937-45945.
69. Bertrand J.A., Thieffine S., Vulpetti A., Cristiani C., Valsasina B., Knapp S., Kalisz H.M., Flocco M. Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol. 333:2003;393-407.